### Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

# Ocrevus® (ocrelizumab)



### Four simple steps to submit your referral.

1 Patient Informati	Please provide copies of front and back of all medical and prescription insurance cards.			
New patient				
Patient's first name		Last name		Middle initial
Sex at birth: Male Female Pre	ferred pronouns	Last 4 digits o	f SSN	Date of birth
Street address				Apt #
City	S	tate		Zip
Home phone	•			
Parent/guardian (if applicable)				
lome phone	Cell phone		E-mail address	
lternate caregiver/contact				
lome phone	Cell phone		E-mail address —	
OK to leave message with alternate	e caregiver/contact			
atient's primary language: Englis	sh Other If other, pleas	se specify		
2 Prescriber Inform	nation	All fields m	ust be completed to	expedite prescription fulfillment.
Date 1	ime	Date medica	ation needed	
Office/clinic/institution name				
Prescriber info: Prescriber's first nam	e		Last name	
Prescriber's title		_ If NP or PA, unde	er direction of Dr	
Office phone				
Office contact and title				
Office street address				
ity				
nfusion location: Patient's home	Prescriber's office Infus	sion site If infusion s	ite, complete informa	•
nfusion info: Infusion site name		Clinic/h	ospital affiliation	
Site street address				Suite #
City		State		Zip
nfusion site contact	Phone	Fax		E-mail
Note: Check the appropriate shipmer	nt options in Section 4: Pres	scribing Information.		
3 Clinical Informat	ion			
Primary ICD-10 code (REQUIRED):	·			
Platelets				
Pregnancy test				
FIRST TWO LOADING DOSES COMP EXPECTED DATE OF FIRST/NEXT IN NKDA Known drug allergies _ Concurrent meds	FUSION			

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

# 4

## **Prescribing Information**

Medication	Dose	Directions	Quantity/Refills	Ship to*:	
Loading Doses (two infusions) Ocrevus® (ocrelizumab)	300mg/10mL SDV Vials are diluted in NS to a final concentration of 1.2mg/mL	Infusion 1: 300mg intravenous in 250mL of 0.9% NS. Infusion 2: (2 weeks later): 300mg intravenous in 250mL of 0.9% NS. Start infusion at 30mL per hour. Increase by 30mL per hour every 30 minutes. Maximum rate: 180mL per hour.  Duration: 2.5 hours or longer	Dispense: 2 vials No refills	Note: Loading doses must be administered in a controlled infusion site. Office Infusion Clinic Unknown	
Maintenance Dose  Ocrevus® (ocrelizumab)	300mg/10mL SDV Vials are diluted in NS to a final concentration of 1.2mg/mL	Option 1: Duration: 3.5 hours or longer  Infuse 600mg intravenous in 500mL of 0.9% NS every 6 months (from date of first loading dose). Start infusion at 40mL per hour. Increase by 40mL per hour every 30 minutes. Maximum rate: 200mL per hour.	Dispense: 2 vials Refills 0 1	Home Office Infusion Clinic Unknown	
		OR			
		Option 2: Duration: 2 hours or longer  Only recommended if no prior serious infusion reaction with any previous Ocrevus infusion.  Infuse 600mg intravenous in 500mL of 0.9% NS every 6 months (from date of first loading dose).  Start infusion at 100mL per hour for the first 15 minutes. Increase to 200mL per hour for the next 15 minutes. Increase to 250mL per hour for the next 30 minutes. Increase to 300mL per hour for the remaining 60 minutes.	Dispense: 2 vials Refills 0 1	Home Office Infusion Clinic Unknown	

All Ocrevus® orders to be administered via pump and peripheral line unless otherwise instructed.

#### Additional Medication and Supplies for Home Infusion

#### **Premedication Orders**

Acetaminophen 650mg PO 30 min prior to infusion; Diphenhydramine 50mg PO 30 min prior to infusion; Methylprednisolone 100mg IV 30 min prior to infusion

Other

#### Fluids for Reconstitution and Administration

0.9% NaCl 250mL x2 (initial dose); 0.9% NaCl 500mL (maintenance dose);

0.9% NaCl Flush 10mL (3 mL pre- and post-infusion to maintain peripheral line patency) 0.9% NACL 50mL

0.9% NACL 30IIIL

0.9% NACL 100mL

#### Hypersensitivity/Anaphylaxis Orders\*

In the event of anaphylactic reaction, stop infusion of drug immediately. Start NS 15mL/hour; 0.9%NS 100mL. Medicate with epinephrine pen auto-injector 0.3mg/0.3mL IM as needed for anaphylaxis. Call \*911\*, physician, or paramedic.

I authorize ancillary supplies or medical equipment necessary such as needles, syringes, etc. to administer the therapy as needed for administration.

Send quantity sufficient for medication infusion

All caregivers and ancillaries to be given per protocol from product package insert. (See next page).

If patient requires specific directions on additional medications or supplies, please provide change on the next page and sign.

Skilled nursing visit as needed to establish venous access, administer medication and assess general status and response to therapy.

\*If nursing services will be required for therapy administration, the home health nurse will call for additional orders per state regulations.

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)



Date Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

# Accredo Additional Medications for Home Infusion Protocol as Per Package Insert

If your patient requires individualized dosing or administering, please cross out directions below, provide desired directions in the box and sign.

Date Signature

Medication	Dose	Directions	
Diphenhydramine IV	50mg/1mL (25mg)	30 minutes prior to infusion, withdraw 0.5ml and inject into 50mL 0.9% NS. In intravenously 101mL/hour over 30 min.	
Diphenhydramine IV	50mg/1mL (50mg)	30 minutes prior to infusion, withdraw 1mL and inject into 50mL 0.9% NS. Infuse intravenously 102mL/hour over 30 min.	
Methylprednsiolone IV	100mg and Diphenhydramine PO	30 min prior to infusion, activate vial, withdraw 1.6mL/100mg, inject into 50mL 0.9% NS. Infuse intravenously 104mL/hour over 30 minutes.	
Methylprednsiolone IV	100mg and Diphenydramine IV SIG	Activate vial, withdraw 1.6mL/100mg. Inject 100mg (1.6mL) intravenous push 0.2mL per minute for 8 minutes may increase to 0.4mL per minute for 4 minutes based on absence of infusion reactions (nausea, vomiting, headache, flushing, vital sign change) 30 minutes prior to Ocrevus.	
Methylprednsiolone IV	125mg SIG	30 minutes prior to infusion, activate vial, withdraw 2mL/125mg, inject into 100mL 0.9% NS. Infuse intravenously 204mL/hour over 30 minutes.	
Methylprednsiolone IV	250mg SIG	30 minutes prior to infusion, activate vial, withdraw 4mL/250mg, inject into 100mL 0.9% NS. Infuse intravenously 208mL/hour over 30 minutes.	
Methylprednsiolone IV	500mg SIG	30 min prior to infusion, activate vial, withdraw 8mL/500mg, inject into 100mL 0.9% NS. Infuse intravenously 216mL/hour over 30 minutes.	
Methylprednisolone IV	125mg vial and Bacteriostatic water	Reconstitute Methylprednisolone 125mg with 2mL of Bacteriostatic water for injection. Withdraw 1.6mL/100mg.	
		a. Inject 100mg (1.6mL) intravenous push 0.2mL per minute for 8 minutes may increase to 0.4mL per minute for 4 minutes based on absence of infusion reactions (nausea, vomiting, headache, flushing, vital sign change) 30 minutes prior to Ocrevus.	
		b. Withdraw 1.6mL and inject into 50mL 0.9% NS. Infuse intravenously 104mL/hour over 30 minutes. 30 minutes prior to Ocrevus.	
Famotidine IV	20mg	30 minutes prior to infusion, withdraw 2mL and inject into 100mL 0.9% NS. Infuse intravenously 204mL/hour over 30 minutes.	
Famotidine IV	10mg	30 minutes prior to infusion, withdraw 1mL and inject into 100mL 0.9% NS. Infuse intravenously 202mL/hour over 30 minutes.	

